scholarly journals A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons in vitro with Oligonucleotide Therapeutics

BIO-PROTOCOL ◽  
2017 ◽  
Vol 7 (16) ◽  
Author(s):  
Julia Alterman ◽  
Andrew Coles ◽  
Lauren Hall ◽  
Neil Aronin ◽  
Anastasia Khvorova ◽  
...  
2013 ◽  
Vol 7 (8) ◽  
pp. 656-664 ◽  
Author(s):  
Ying-Ying Huang ◽  
Kazuya Nagata ◽  
Clark E Tedford ◽  
Michael R. Hamblin

2013 ◽  
Vol 31 (3) ◽  
pp. 670-683 ◽  
Author(s):  
Juliette Janson ◽  
Susanna Eketjäll ◽  
Karin Tunblad ◽  
Fredrik Jeppsson ◽  
Stefan Von Berg ◽  
...  

2009 ◽  
Vol 188 (2) ◽  
pp. 98-103 ◽  
Author(s):  
Andrew J. Olaharski ◽  
Hirdesh Uppal ◽  
Matthew Cooper ◽  
Stefan Platz ◽  
Tanja S. Zabka ◽  
...  

2002 ◽  
Vol 12 (3) ◽  
pp. 487-492 ◽  
Author(s):  
N. Doi ◽  
H. Takashima ◽  
M. Kinjo ◽  
K. Sakata ◽  
Y. Kawahashi ◽  
...  

2020 ◽  
Author(s):  
Anna Slita ◽  
Prakirth Govardhanam ◽  
Ida Opstad ◽  
Didem Sen Karaman ◽  
Jessica Rosenholm

<p><strong>Introduction</strong></p> <p>Since antibiotics were discovered, bacteria have demonstrated the ability to develop resistance by many different mechanisms. According to WHO reports from 2014, there has been an alarming increase in the antibiotic resistant bacterial strains in most parts of the world<sup>1</sup>. Our previous results showed that a nanoantibiotic (NAB) design created in our laboratory<sup>2</sup>, composed of a cerium oxide core, mesoporous silica shell loaded with capsaicin, and a chitosan coating, are effective against planktonic E. coli. However, most of the pathogenic bacteria form biofilms during infections. That is why the next stage of studying NAB is to determine whether they are effective against biofilms of different species. Moreover, the results of NAB efficiency against planktonic E. coli did not clearly show the contribution of the antibiotic drug component of NAB – capsaicin. Hence, the first step of the current study is to determine whether and to what degree, mesoporous silica nanoparticles (MSN) – serving as NAB model in this case - penetrate biofilms as a function of particle shape and surface coating; as well as finding the efficient concentration of capsaicin against E. coli and S. aureus  to optimize the NAB dosing against biofilms.</p> <p><strong> </strong></p> <p><strong>Aim</strong></p> <p>To check in vitro penetration of MSN on S. aureus biofilm and antibacterial activity of NAB and pure capsaicin on E. coli and S. aureus biofilms.</p> <p><strong><br />Methods</strong></p> <p>To investigate NAB efficiency on biofilms MBEC-high-throughput assay<sup>3</sup> was performed. Equal biofilms formed on peg-lids were incubated with different concentrations of NAB and capsaicin. After different time point biofilms were sonicated and plated on agar plated to perform CFU counting. To determine the efficient concentration of capsaicin, biofilms were formed in 12 well plates and then incubated with different concentrations of capsaicin. To visualize inhibitory effect, plating for CFU counting and Resazurin assay were applied. To evaluate the penetration of particles, labeled and non-labeled particles were added to fully grown St. aureus biofilms, incubated and visualized with confocal microscopy and structured illumination microscopy.</p> <p><strong> </strong></p> <p><strong>Results</strong></p> <ol> <li>Through two different microscopy techniques penetration of particles into biofilm and their localization next to bacteria cells were observed.</li> <li>In MBEC-high-throughput assay no inhibitory effect of NAB against E. coli biofilms was detected in comparison with untreated bacteria.</li> <li>Resazurin assay and CFU counting method allowed us to determine the most efficient concentration of capsaicin against E. coli and St. aureus biofilms.</li> </ol> <p><strong> </strong></p> <p><strong>Conclusion</strong></p> <ol> <li>Use of MSN and NAB in particular to deliver active antibacterial agents inside the biofilm is justified.</li> <li>We cannot claim that NAB does not demonstrate any activity against E. coli biofilms, though we can suggest that the peg-lid set up is not sufficient for the NAB design. Further experiments are required.</li> <li>The next step is to test different concentrations of NAB against biofilms with more appropriate methods than MBEC-high-throughput assay. These results will allow us to make conclusions about the benefits of NAB in comparison with pure capsaicin.</li> </ol> <p><strong> </strong></p> <p><strong>References</strong></p> <ol> <li>Govardhanam, N.P. (2017). Development of nanoantibiotics and evaluation via in vitro and in vivo imaging. University of Turku, Finland.</li> <li>Ventola, C. Lee. Pharmacy and Therapeutics 40.4: 277, 2015</li> <li>Harrison, J. et al., BMC microbiology 5(1), 53, 2005.</li> </ol>


2016 ◽  
Vol 21 (8) ◽  
pp. 804-815 ◽  
Author(s):  
X. Medda ◽  
L. Mertens ◽  
S. Versweyveld ◽  
A. Diels ◽  
L. Barnham ◽  
...  

Tau aggregation is the pathological hallmark that best correlates with the progression of Alzheimer’s disease (AD). The presence of neurofibrillary tangles (NFTs), formed of hyperphosphorylated tau, leads to neuronal dysfunction and loss, and is directly associated with the cognitive decline observed in AD patients. The limited success in targeting β-amyloid pathologies has reinforced the hypothesis of blocking tau phosphorylation, aggregation, and/or spreading as alternative therapeutic entry points to treat AD. Identification of novel therapies requires disease-relevant and scalable assays capable of reproducing key features of the pathology in an in vitro setting. Here we use induced pluripotent stem cells (iPSCs) as a virtually unlimited source of human cortical neurons to develop a robust and scalable tau aggregation model compatible with high-throughput screening (HTS). We downscaled cell culture conditions to 384-well plate format and used Matrigel to introduce an extra physical protection against cell detachment that reduces shearing stress and better recapitulates pathological conditions. We complemented the assay with AlphaLISA technology for the detection of tau aggregates in a high-throughput-compatible format. The assay is reproducible across users and works with different commercially available iPSC lines, representing a highly translational tool for the identification of novel treatments against tauopathies, including AD.


2015 ◽  
Vol 2 (3) ◽  
pp. 217-229 ◽  
Author(s):  
Antonina M. Monaco ◽  
◽  
Anastasiya Moskalyuk ◽  
Jaroslaw Motylewski ◽  
Farnoosh Vahidpour ◽  
...  

2018 ◽  
Vol 78 (4) ◽  
pp. 297-304
Author(s):  
Mohammad Iqbal Hossain Bhuiyan ◽  
Seong Yun Kim ◽  
Kyung-Ok Cho

Sign in / Sign up

Export Citation Format

Share Document